E-LIB Suche - Ergebnisse für: Tachas, George

1

A phase 2 open-label study of the safety and efficacy of we..:

Woodcock, Ian R. ; Tachas, George ; Desem, Nuket...
PLOS ONE. 19 (2024) 1 - p. e0294847 , 2024

Link: https://doi.org/10.1371/..

2

Neuro-PASC is characterized by enhanced CD4+ and diminished..:

Visvabharathy, Lavanya ; Hanson, Barbara A. ; Orban, Zachary S....
Frontiers in Immunology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

3

Plasma proteomics show altered inflammatory and mitochondri..:

Hanson, Barbara A. ; Visvabharathy, Lavanya ; Orban, Zachary S....
Brain, Behavior, and Immunity. 114 (2023) - p. 462-474 , 2023

Link: https://doi.org/10.1016/..

4

Corrigendum: Neuro-PASC is characterized by enhanced CD4+ a..:

Visvabharathy, Lavanya ; Hanson, Barbara A. ; Orban, Zachary S....
Frontiers in Immunology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

5

A randomised, open-label, parallel group phase 2 study of a..:

Trainer, Peter J ; Newell-Price, John D C ; Ayuk, John...
European Journal of Endocrinology. 179 (2018) 2 - p. 97-108 , 2018

Link: https://doi.org/10.1530/..

6

Effects of CD49d-targeted antisense-oligonucleotide on α4 i..:

Duchartre, Yann ; Bachl, Stefanie ; Kim, Hye Na...
PLOS ONE. 12 (2017) 11 - p. e0187684 , 2017

Link: https://doi.org/10.1371/..

7

CD49d antisense drug ATL1102 reduces disease activity in pa..:

Limmroth, Volker ; Barkhof, Frederik ; Desem, Nuket...
Neurology. 83 (2014) 20 - p. 1780-1788 , 2014

Link: https://doi.org/10.1212/..

8

Gene transfection of the HuLy-m2 (Leu-9) antigen into mouse..:

Sandrin, Mauro S. ; Erin Lovering, K. ; Tachas, George..
Immunogenetics. 25 (1987) 5 - p. 279-283 , 1987

Link: https://doi.org/10.1007/..

9

A randomised, open-label, parallel group phase 2 study of a..:

Trainer, Peter J ; Newell-price, John D C ; Ayuk, John...
Trainer , P J , Newell-price , J D C , Ayuk , J , Aylwin , S J B , Rees , A , Drake , W , Chanson , P , Brue , T , Webb , S M , Fajardo , C , Aller , J , Mccormack , A I , Torpy , D J , Tachas , G , Atley , L , Ryder , D & Bidlingmaier , M 2018 , ' A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly ' , European Journal of Endocrinology , vol. 179 , no. 2 , pp. 97-108 . https://doi.org/10.1530/EJE-18-0138. , 2018

Link: https://research.manches..

10

A randomised, open-label, parallel group phase 2 study of a..:

Trainer, Peter J ; Newell-Price, John D. C ; Ayuk, John...
info:eu-repo/semantics/altIdentifier/doi/10.1530/EJE-18-0138. , 2018

Link: https://hal.archives-ouv..

11

A randomised, open-label, parallel group phase 2 study of a..:

Trainer, Peter J ; Newell-Price, John D. C ; Ayuk, John...
European journal of endocrinology. , 2018

Link: https://ddd.uab.cat/reco..

12

A randomised, open-label, parallel group phase 2 study of a..:

Trainer, Peter J ; Newell-Price, John D. C ; Ayuk, John...
info:eu-repo/semantics/altIdentifier/doi/10.1530/EJE-18-0138. , 2018

Link: https://hal.science/hal-..

13

Change in the MRI Central reading fat fraction, cross secti..:

Ian R. Woodcock ; George Tachas ; Nuket Desem...
doi:10.1371/journal.pone.0294847.t006. , 2024

Link: https://doi.org/10.1371/..

14

Pre-clinical data using the mdx mouse model of DMD to test ..:

Ian R. Woodcock ; George Tachas ; Nuket Desem...
doi:10.1371/journal.pone.0294847.g002. , 2024

Link: https://doi.org/10.1371/..

15

Inclusion and Exclusion criteria for the clinical trial:

Ian R. Woodcock ; George Tachas ; Nuket Desem...
doi:10.1371/journal.pone.0294847.s002. , 2024

Link: https://doi.org/10.1371/..